文献速递血脂与心血管预防冠心病

贝派地酸对总心血管事件的影响:CLEAR Outcomes随机临床试验的预设分析

Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2024-01-01

该预设分析基于CLEAR Outcomes试验,纳入13 970例他汀不耐受的高心血管风险患者,随机接受贝派地酸或安慰剂治疗。

要点

  • 贝派地酸显著降低他汀不耐受患者的总MACE-4、MACE-3、心梗和冠脉血运重建风险。
  • 贝派地酸对卒中总发生率无显著影响(HR 0.80,95%CI 0.63-1.03)。
  • 随着患者经历MACE事件次数增加,贝派地酸的保护HR更低。

核心结论

  • 在他汀不耐受且LDL-C升高的高心血管风险患者中,贝派地酸降低LDL-C可减少总心血管事件数。

研究设计与样本

  • CLEAR Outcomes试验的预设分析,纳入13 970例有心血管疾病或高风险、高胆固醇血症且无法耐受指南推荐他汀的患者,随机每日接受贝派地酸或安慰剂。
  • 患者平均(SD)年龄65(9)岁,男性7230例(51.8%),9764例(69.9%)有既往动脉粥样硬化性心血管疾病,基线LDL-C水平139 mg/dL。

主要发现

  • 贝派地酸治疗6个月时LDL-C降低21%,hsCRP降低22%。
  • 共记录1746例经裁定首次MACE-4事件和612例患者的915次额外MACE事件,冠脉血运重建占首次事件的32.8%(573/1746)和额外事件的69.4%(635/915)。
  • 贝派地酸降低MACE-4总发生率风险(HR 0.80;95%CI 0.72-0.89;P <.001)、MACE-3(HR 0.83;95%CI 0.73-0.93;P = .002)、心肌梗死(HR 0.69;95%CI 0.58-0.83;P < .001)和冠脉血运重建(HR 0.78;95%CI 0.68-0.89;P < .001)。
  • 卒中无统计学显著差异(HR 0.80;95%CI 0.63-1.03)。
  • 随着患者经历MACE事件次数增加,贝派地酸保护作用的HR更低。

临床怎么用

  • 对于他汀不耐受的高心血管风险且LDL-C升高的患者,可考虑使用贝派地酸以降低总心血管事件负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The ATP citrate lyase (ACL) inhibitor, bempedoic acid, reduces low-density lipoprotein cholesterol (LDL-C) level and major adverse cardiovascular events (MACE) by 13% in patients at high cardiovascular risk with intolerance of statin and high-intensity statin medications. The effects of bempedoic acid on total cardiovascular events remain unknown. OBJECTIVE: To determine the impact of bempedoic acid on the total incidence of MACE. DESIGN, SETTING, AND PARTICIPANTS: Included in this prespecified analysis of the Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial were patients with, or at high risk for, cardiovascular disease, with hypercholesterolemia and inability to take guideline-recommended statins. Study data were analyzed from December 2016 to November 2022. INTERVENTIONS: Patients were randomly assigned to treatment with bempedoic acid or placebo daily. MAIN OUTCOMES AND MEASURES: The primary end point was the time to first event for a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization (MACE-4). The key secondary end point was time to first event for cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (MACE-3). This prespecified analysis compared the total number of cardiovascular events in the treatment groups. RESULTS: A total of 13 970 patients (mean [SD] age, 65 [9] years; 7230 male [51.8%]) were included in the study. A total of 9764 participants (69.9%) had prior atherosclerotic cardiovascular disease and a baseline LDL-C level of 139 mg/dL; treatment with bempedoic acid resulted in a 21% reduction in LDL-C level and a 22% reduction in high-sensitivity C-reactive protein (hsCRP) level at 6 months. Median (IQR) follow-up was 3.4 (3.1-3.9) years. A total of 1746 positively adjudicated first MACE-4 events and 915 additional MACE events in 612 patients were recorded, with coronary revascularization representing 32.8% (573 of 1746) of first events and 69.4% (635 of 915) of additional events. For the total incidence of cardiovascular events, treatment with bempedoic acid was associated with a reduction in risk of MACE-4 (hazard ratio [HR], 0.80; 95% CI, 0.72-0.89; P <.001), MACE-3 (HR, 0.83; 95% CI, 0.73-0.93; P = .002), myocardial infarction (HR, 0.69; 95% CI, 0.58-0.83; P < .001), and coronary revascularization (HR, 0.78; 95% CI, 0.68-0.89; P <.001), although no statistically significant difference was observed for stroke (HR, 0.80; 95% CI, 0.63-1.03). A lower HR for protection with bempedoic acid was observed with increasing number of MACE events experienced by patients. CONCLUSION AND RELEVANCE: Lowering LDL-C level with bempedoic acid reduced the total number of cardiovascular events in patients with high cardiovascular risk, statin therapy intolerance, and elevated LDL-C levels.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Nicholls SJ, Nelson AJ, Lincoff AM, et al. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 38231501. doi:10.1001/jamacardio.2023.5155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。